openPR Logo
Press release

Burgeoning Demand for Immune Thrombocytopenia Treatment to Fuel Market Growth Thorough the COVID-19 Crisis Period

12-01-2020 04:54 AM CET | Health & Medicine

Press release from: Persistence Market Research

Immune Thrombocytopenia is an autoimmune disorder that results in an abnormally low level of platelets. Immune thrombocytopenia is asymptomatic bleeding disorders. Symptoms appear only after platelet count is extremely low. Those symptoms include petechiae, skin bruises, gum bleeding and others. According to the National Organization of Rare Diseases, the immune thrombocytopenia incidence in the U.S. is 3.3 per 100,000 adults/year. Estimated annual prevalence 9.5/100,000 in adults and 5.3/100,000 among children. The male population is more significantly affected by immune thrombocytopenia when compared to the female population. Immune thrombocytopenia treatment includes corticosteroids and others symptomatic treatment drugs. FDA approved anti-D for immune thrombocytopenia and designated as an orphan drug. Along with these, anti CD20 antibody, rituximab, Sandimmune, Danocrine, Imuran, Cytoxan, vincristine and other drugs are used as immune thrombocytopenia treatment.

Request to Sample report @

Immune Thrombocytopenia Treatment Market: Drivers and Restraints

Orphan drugs may benefit multi-year regulatory exclusivity during which there is no submission of abbreviated NDA /505(b) applications by another manufacturer and it expected fuel immune thrombocytopenia treatment market. Along with these, orphan drugs receive exclusivity period of 7 Years. Exclusivity is meant to encourage investment in research and development by providing innovators with exclusive use for a limited time and expected to boost the immune thrombocytopenia treatment market. This exclusivity operates independently of patent protection and protect the product from the generic competition, even if there is no patent covering the product and it is expected to fuel the growth of immune thrombocytopenia treatment market. In the US, the FDA will not grant final marketing approval to a generic competitor for a New Chemical Entity (NCE) until the expiration of the regulatory exclusivity period that commences upon the first marketing authorization of the reference product. The FDA will accept the filing of an Abbreviated New Drug Application (ANDA) containing a patent challenge one year before the end of this regulatory exclusivity period and boosted the immune thrombocytopenia treatment market. Further, increasing government support in order to advance the research activities is expected to fuel the growth immune thrombocytopenia treatment market. European Union supports manufacturers which take part in the research for rare diseases through its multiannual framework programmes for research and technological development. It offers financial grants to the research proposals and it boosts the immune thrombocytopenia treatment market. Under the FP7, EU granted over €620 million for 120 collaborative projects which are associated with rare diseases and it is expected to fuel immune thrombocytopenia treatment market. All these factors act as a potential driver for the burgeoning growth of immune thrombocytopenia treatment market.

How the Coronavirus Threat has Taken Global Business into Uncharted Waters

Immune Thrombocytopenia Treatment Market: Segmentation

Segmentation on the Drug Type

Monoclonal Antibodies
Segmentation on the Distribution Channel

Hospital Pharmacies
Specialty Pharmacies
Immune Thrombocytopenia Treatment Market: Overview

The global Immune Thrombocytopenia Treatment market has witnessed robust growth due to increasing demand for devices. Immune thrombocytopenia treatment drugs are granted orphan designation by regulatory bodies has high flexibility over the pricing of drugs. This has given added advantage to developers along with regulatory exclusivity. It is further supported by lack of alternative immune thrombocytopenia treatment options further boosted the growth of immune thrombocytopenia treatment market. Immune thrombocytopenia treatment market has witnessed monopolistic power due to limited players and limited to no competition. Monopolistic nature of the market is expected to offer high immune thrombocytopenia treatment market share to the manufacturers during the forecast period. Along with these, increasing focus of legislative bodies on developing reimbursement policies has fueled the immune thrombocytopenia treatment market.

Request to View TOC @

Immune Thrombocytopenia Treatment Market: Region-Wise Overview

The global Immune Thrombocytopenia Treatment market can be segmented into the following regions – North America, Latin America, Europe, the Asia Pacific Excluding China, China and the Middle East & Africa. North America immune thrombocytopenia treatment market is expected to remain dominant in the global immune thrombocytopenia treatment market. Europe immune thrombocytopenia treatment market is expected to remain the second dominant region in the global immune thrombocytopenia treatment market. Asia Pacific Excluding China immune thrombocytopenia treatment market is expected to register fast CAGR during the forecast period in global immune thrombocytopenia treatment market. Latin America and Middle East & Africa accounts for a small market share in global immune thrombocytopenia treatment market

Immune Thrombocytopenia Treatment Market: Market Participants

Key participants operating in the Immune Thrombocytopenia Treatment market include ,

Novartis AG
Amgen Inc.
Emergent BioSolutions
Octapharma USA.
Pfizer Inc
Roche Holding AG
Merck & Company, Inc..
Players in immune thrombocytopenia treatment market are mainly focusing on collaborations and partnerships to keep pace with the competition and develop new products.

For in-depth competitive analysis, buy now@

Contact Us:
305 Broadway
7th Floor
New York City, NY 10007
United States
U.S.A - Canada Toll-Free: 800-961-0353

Persistence Market Research (PMR) is an innovative and specialized publisher of market intelligence reports and consulting services. Prompt delivery, in-depth research, and high quality are the sacrosanct principles of PersistenceMarketResearch.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Burgeoning Demand for Immune Thrombocytopenia Treatment to Fuel Market Growth Thorough the COVID-19 Crisis Period here

News-ID: 2199178 • Views: 140

More Releases from Persistence Market Research

The Fta Buccal Collection Kits Market to be bolstered by technology
FTA buccal collection kits is used in the collection and analysis of DNA most commonly from the buccal cells or blood. Collection of buccal samples through FTA cards are painless and relatively easily collected, are often preferred source. There are several buccal collection methods such as brushes, swabs, FTA or IsoCode cards. Among all, FTA cards mostly used methods, and this is due to FTA card produce DNA that
The Syringeless Based Filters Market to reap the benefits of technology in the n …
A syringeless based filter offers an easier, faster method of removing particulates from samples being prepared for high-performance liquid chromatography (HPLC) analysis. Moreover, that syringeless based filter can add up the money savings, plus the time saved from cutting multiple consumables out of the sample preparation process. Syringeless based filters serve the rapid single step procedure, due to which sample loss is reduced. A shrill trend in the application of
The Whatman Indicating Mini Cards Market to identify its growth parameters betwe …
Whatman indicating mini cards offers a system through which simplifying the purification, isolation and storage of nucleic acids is possible in a variety of research and diagnostic operations. Additionally, whatman indicating mini cards market has simplifies the processing and handling of nucleic acids with a wide range of applications. It is based on the chemicals, present on whatman indicating mini cards which can denature proteins, lyse cells and protect nucleic
The Pediatric Respiratory Devices Market to witness livewire performance between …
Pediatric respiratory devices diagnose diseases and conditions from birth through age 21. Pediatric subpopulations are categories as neonates, infants, children and adolescent. Recently, the Food and Drug Administration (FDA) of the United States has been focusing on “Unmet Medical Needs” in the pediatric patients and orphan diseases, and policies to protect pediatric patients in clinical trials for medical devices have been established and reinforced. For instance, vessel sealing devices jejunal

All 5 Releases

More Releases for Immune

Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an
Immune Health Supplements: Best Way to Boost Your Immune System
ResearchMoz include new market research report "Global Immune Health Supplements Market Research Report 2019" to its huge collection of research reports. Immune Health Supplements refer to the product which could improve human immune health. The global Immune Health Supplements market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. Learn more Through Sample Report
Immune Health Supplements Market
The immune health supplements apart from providing resistance to infection and disease, also provide preventive measures that help to maintain immune system. The immune system is a complicated network of various functions, which all together help to prevent against infective agents such as pathogenic bacteria and viruses. Healthy immune system easily recognizes foreign agents. The cells of immune system are different which mainly include the lymphocytes, or T-cells that fight
Immune Checkpoint Inhibitors Benefits to avoid over-activation of the healthy ce …
Immune Checkpoint Inhibitors Market: Overview The immune system of human body depends on multiple checkpoints or immunological breaks, which avoid over-activation of the healthy cells or immune system. Tumor or cancerous cells often take advantage of these checkpoints to escape detection and fight against immune system. To struggle against such cancer cells, the focus of the scientists and drug developers is gradually diverting towards immunotherapeutics, which makes use of the
03-17-2016 | Health & Medicine
Extracorporal Modified Immune Therapy (EMIT)
A tumor patient usually does not die from a benign tumor, but from a malignant tumor that maintains an uninhibited proliferation, which in turn interferes fatally with the vital functions of other organs. Apart from surgical procedures at an early stage, conventional cancer therapy is based on the philosophy that cancer cells should be destroyed with various destructive methods such as chemotherapy, radiation therapy, TKI, monoclonal antibodies, etc. All immunological research
04-26-2011 | Health & Medicine
Apogen Capsule for Immune Wellness ( FEBICO)
For better living and brighter futures, the working class tends to tire themselves outshine others in the work fields due to tough competition. Stress and pressure are built up day by day and people often neglect their health conditions. Bad health can cause weakening the immune system of the body, low moral and spirit, physical fatigue, and nutritional imbalance. These conditions can prevent one from maintaining in top form, and